SMAD2 and breast cancer: In contrast to our findings in pancreatic CAFs, authors showed that SMAD2/3 phosphorylation was unaffected upon myoferlin silencing but revealed an impact of myoferlin on TGFß secretion and autocrine signaling in breast cancer cell lines.